Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.
| 49.36 | |
| 52.81 | |
| - | |
| 53.12 | |
| 49.3 | |
| 30.43-60.2698 | |
| 20 656 M | |
| 45.2844 | |
| 418 M | |
| 2 757 M | |
| 0.46 | |
| 0.0034 | |
| 0.759 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
How far off is TT Electronics plc (LON:TTG) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by projecting its future cash flows ...
- Agenus to receive $35M upfront with $100M in milestones plus royalties - Betta receives exclusive license of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) in Greater China LEXINGTON, Mass...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
